Sponsor:
Aurinia Pharmaceuticals Inc.
Code:
NCT07611214
Conditions
Lupus Nephritis
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
LUPKYNIS
belimumab, obinutuzumab or anifrolumab
mycophenolic acid analog (MPAA)
corticosteroid
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2026-06-28. This information was provided to ClinicalTrials.gov by Aurinia Pharmaceuticals Inc. on 2026-06-12.